Human papillomavirus vaccine recombinant octavalent - Merck

Drug Profile

Human papillomavirus vaccine recombinant octavalent - Merck

Alternative Names: Octavalent HPV VLP vaccine - Merck; Octavalent human papillomavirus (types 6, 11, 16, 18, 31, 45, 52, and 58) L1 virus-like particle vaccine - Merck; V-502

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 10 Feb 2014 Discontinued - Phase-I for Cervical cancer in Australia (IM)
  • 10 Feb 2014 Discontinued - Phase-I for Cervical cancer in USA (IM)
  • 10 Feb 2014 Discontinued - Phase-I for Human papillomavirus infections in Australia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top